Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for doxorubicin liposomal pegylated

  1. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA389

  2. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

    Technology appraisal guidance
    Published
    22 May 2013
    View recommendations

    Sections for TA285

  3. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  4. Ovarian cancer: recognition and initial management (CG122)

    This guideline covers detecting, diagnosing and treating women (aged 18 and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.

    Clinical guideline
    Last updated
    2 October 2023
    View recommendations

    Sections for CG122

  5. Past appeals and decisions

    Past technology appraisal appeals and decisions

  6. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (TA45)

    This guidance has been updated and replaced by NICE technology appraisal guidance 91.

    Technology appraisal guidance
    Published
    19 July 2002

  7. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Technology appraisal guidance
    Published
    25 May 2005